On 5 March 2024 the board of directors of ChromoGenics resolved, subject to subsequent approval by the extraordinary general meeting on 5 April 2024, on a directed share issue of 2,505,885 shares. The extraordinary general meeting on 5 April 2024 resolved, in accordance with the board of directors' proposal, to approve the board of directors' resolution to carry out the Directed Issue. Consequently, the board of directors has today, on 5 April 2024, resolved on allocation of shares to Färna Invest AB, Parment Förvaltning AB, Investment Aktiebolaget Balticum, Barbro Brandt, Johan Hedin, Anders Brännström, Fredrik Fränding, Fredrik Andersson and Andreas Jaeger. All investors in the Directed Issue have subscribed for and been allocated shares in a total approximate amount of SEK 16 million corresponding to 2,505,885 new shares. In accordance with what was announced on 5 March 2024 ChromoGenics has, in connection with the Directed Issue, also entered into loan agreements, on market terms, with among others with Parment Förvaltning AB to an amount of SEK 5 million, of which SEK 2.5 million has been set off against shares in the Directed Issue.

The subscription price in the Directed Issue amounted to SEK 6.44 per share, corresponding to approximately 5 per cent discount compared to the closing price of the Company's share on Nasdaq First North Growth Market prior to the board of directors' resolution on the Directed Issue. Since the subscription price was determined through an accelerated bookbuilding procedure, it is the board of directors' assessment that the subscription price reflects current market conditions and is thus market-based.

Through the Directed Issue, the number of shares in the Company will increase by 2,505,885 shares, from 4,124,966 to 6,630,851, and the share capital will increase by SEK 13,782,367.5, from SEK 22,687,313 SEK to SEK 36,469,680.5. This corresponds to a dilution effect of approximately 37.8 per cent of the shares and votes in the Company.

Advisors

Vator Securities is Sole Bookrunner and issuing agent and Advokatfirman Schjødt is legal advisor to ChromoGenics in connection with the Directed Issue.

For more information, please contact:

Fredrik Fränding, CEO
Tel: +46(0) 18 430 0430
Email: info@chromogenics.com

About this information

The information was submitted for publication, through the agency of the contact persons set out above, at 15.30 CEST on 5 April 2024.

About ChromoGenics

ChromoGenics is a proptech company that produces smart dynamic glass, improving indoor environment and well-being while reducing energy consumption, operational costs, and climate impact in real estate. The product, ConverLight® dynamic glass, is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic films. The result is a dynamic foil that can be laminated into glass, providing effective sun protection in buildings and reducing environmental impact in production, transportation, and usage. The dynamic foil is easy to transport and can be applied by local partners in the glass industry, avoiding the need for long-distance shipments of bulky glass. All products from ChromoGenics prioritize environmental and health aspects, focusing on eco-friendly materials, reduced energy consumption, increased access to daylight and views, and improved indoor comfort.

ChromoGenics' production facility in Uppsala has been partly financed through conditional loans from the Swedish Energy Agency. ChromoGenics' stock (CHRO) is listed on the Nasdaq First North Growth Market, with Vator Securities serving as the Certified Adviser.

Important information

Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in ChromoGenics in any jurisdiction, either from ChromoGenics or from anyone else.

This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 ("the Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to "qualified investors" in that Member State as defined in the Prospectus Regulation.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act"), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook.